Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

Tuberculosis is the leading bacterial cause of death globally. In 2021, 10·6 million people developed symptomatic tuberculosis and 1·6 million died. Seven promising vaccine candidates that aim to prevent tuberculosis disease in adolescents and adults are currently in late-stage clinical trials. Conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Kristin N, Churchyard, Gavin, Cobelens, Frank, Hanekom, Willem A, Hill, Philip C, Lopman, Benjamin, Mave, Vidya, Rangaka, Molebogeng X, Vekemans, Johan, White, Richard G, Wong, Emily B, Martinez, Leonardo, García-Basteiro, Alberto L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2023
Materias:
Personal View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393779/
https://www.ncbi.nlm.nih.gov/pubmed/37329893
http://dx.doi.org/10.1016/S2666-5247(23)00112-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393779/
https://www.ncbi.nlm.nih.gov/pubmed/37329893
http://dx.doi.org/10.1016/S2666-5247(23)00112-X

Ejemplares similares